Beyond Metabolic Health: The Emerging Frontier of Incretin Therapies in Addiction

The landscape of metabolic medicine has been fundamentally rewritten over the past decade by glucagon-like peptide-1 receptor agonists (GLP-1RAs). Originally approved to improve glycemic control in type 2 diabetes, these agents have revolutionized the management of obesity and demonstrated profound cardioprotective and neuroprotective benefits. Yet, one of the most compelling and rapidly evolving frontiers of GLP-1RA research lies entirely outside the endocrine system: the treatment of substance use disorders, particularly alcohol use disorder (AUD).

Anecdotal reports and real-world database analyses have long suggested that patients taking semaglutide or liraglutide experience a spontaneous, unexpected reduction in their desire to drink alcohol. Now, robust clinical trial data are catching up to these observations. For healthcare providers navigating the complex, often discouraging reality of addiction medicine, understanding the neurobiology, clinical efficacy, and practical implications of this shifting paradigm is no longer optional.

Why It Matters

Overcoming Stagnation in AUD Therapeutics

Alcohol use is a leading modifiable cause of morbidity and mortality worldwide, accounting for approximately 4% to 5% of the global disease burden and killing an estimated 2.6 million people annually. In the United States alone, excessive alcohol use is responsible for roughly 178,000 deaths each year, driven significantly by an alarming acceleration in alcohol-associated liver disease mortality.

The Severe Burden and Treatment Gap

Despite this catastrophic public health impact, the therapeutic arsenal for AUD has remained stagnant for decades. Only three medications are currently approved by the U.S. Food and Drug Administration (FDA) to treat AUD: disulfiram, naltrexone, and acamprosate. To put this lack of innovation into perspective, since disulfiram was approved in 1951, the FDA has approved only two subsequent unique medications for AUD. This stands in stark contrast to fields like diabetes care, where newly approved mechanisms outnumber AUD therapies twentyfold.

Furthermore, existing medications are vastly underutilized. Less than 10% of individuals meeting the criteria for AUD receive any form of treatment, and less than 2% are prescribed pharmacotherapy. This massive treatment gap is compounded by modest clinical efficacy; up to 40% of patients relapse within the first three years of standard treatment, and current therapies often exhibit small effect sizes in clinical trials. Providers urgently need effective, well-tolerated medications that can bypass traditional barriers to care.

The Neurobiological Overlap of Reward

Why do metabolic hormones influence addictive behaviors? The answer lies in the shared neural architecture of survival. The endogenous GLP-1 peptide is a 30-amino acid hormone produced primarily by intestinal L-cells in response to food intake, but it is also synthesized centrally within the nucleus tractus solitarius of the medulla oblongata. From there, GLP-1 pathways project extensively to brain regions intimately tied to reward processing, motivation, and addiction, including the ventral striatum, dorsal striatum, and septal area.

Drugs of abuse and alcohol hijack the exact same mesolimbic dopamine reward system that evolved to reinforce natural rewards like food. Because GLP-1 acts centrally to modulate dopamine homeostasis and dampen the reinforcing value of food, it is uniquely positioned to modulate the incentive salience of exogenous substances.

Recent neuroimaging and biomarker data confirm this central engagement in humans:

• Attenuating Cue Reactivity: Double-blind, randomized controlled trials using functional magnetic resonance imaging (fMRI) demonstrate that GLP-1RA therapy significantly attenuates alcohol cue reactivity in key reward centers, including the ventral striatum and septal area. When exposed to alcohol-associated stimuli, patients treated with a GLP-1RA exhibit a marked reduction in the neurological “craving” signature.
• Modulating Dopamine Transporters: Molecular imaging with single-photon emission computed tomography (SPECT) has revealed that chronic GLP-1RA administration reduces striatal dopamine transporter (DAT) availability in patients with AUD. This structural adaptation helps regulate extracellular dopamine homeostasis, effectively diminishing the neurochemical spike and subsequent crash that fuel compulsive consumption.

By targeting the core pathology of addiction—incentive salience and dysregulated reward signaling—GLP-1RAs offer a novel, mechanistically distinct therapeutic target that could revolutionize how providers approach substance dependence.

Who It Affects

Identifying Patient Phenotypes

As incretin therapies move forward in addiction medicine, clinical data suggest that their efficacy is highly dependent on patient phenotypes. Understanding who benefits most allows providers to envision targeted, personalized interventions.

The Comorbid Obesity and Overweight Phenotype

The most robust clinical trial evidence for GLP-1RAs in treatment-seeking AUD populations is concentrated among individuals with a body mass index (BMI) corresponding to overweight or obesity.

In a landmark 26-week randomized, double-blind, placebo-controlled trial evaluating once-weekly semaglutide (2.4 mg) in patients with moderate-to-severe AUD and comorbid obesity (BMI ≥ 30 kg/m^2), the medication demonstrated exceptional therapeutic efficacy. Patients treated with semaglutide experienced a dramatic reduction in heavy drinking days of 41.1 percentage points from baseline, compared to a 26.4 percentage point reduction in the placebo group. This generated an estimated treatment difference of -13.7 percentage points, showing a highly significant clinical benefit.

This success mirrors exploratory subgroup data from earlier trials using exenatide. While once-weekly exenatide did not show a statistically significant reduction in heavy drinking days across a broad, unselected AUD cohort, post hoc exploratory analyses revealed a powerful response in the obese subgroup (BMI > 30 kg/m^2), where it significantly reduced both heavy drinking days and total alcohol intake.

Interestingly, a significant association exists between the degree of weight loss and the reduction of heavy drinking days in patients taking active GLP-1RA therapy, a correlation completely absent in placebo cohorts. This underscores a fascinating phenotypic overlap: patients suffering from dysregulated, compulsive patterns governing both caloric intake and alcohol consumption seem to possess a shared neurobiological vulnerability that is highly responsive to incretin modulation. Given that millions of adults concurrently experience obesity and heavy alcohol use, this phenotype represents an ideal target for dual-benefit clinical intervention.

Lean Populations and Glycemic Risks

Conversely, caution may be warranted in lean individuals. In the exenatide AUD trial, lean patients with a BMI < 25 kg/m^2 who received the active drug actually experienced an increase in heavy drinking days compared to placebo.

While the exact mechanism remains under investigation, researchers hypothesize that lean individuals may experience more pronounced drops in blood glucose following GLP-1RA administration, and transient hypoglycemia or rapid glycemic shifts are known neurochemical triggers for alcohol craving. Therefore, until larger trials clarify safety and efficacy profiles across non-obese populations, broad off-label use in lean individuals cannot be routinely endorsed.

Treatment-Seeking vs. Non-Treatment-Seeking Behavior

The behavioral orientation of the patient also influences the expression of the medication’s effects:

• Non-Treatment-Seeking Populations: A 9-week phase 2 randomized trial evaluated low-dose semaglutide (up to 1.0 mg/week) in adults with AUD who were not actively seeking treatment or trying to cut down. Remarkably, even in the absence of a volitional intent to reduce drinking, semaglutide significantly reduced weekly alcohol craving and reduced drinks per drinking day. It also significantly decreased the total amount of alcohol voluntarily consumed during objective human laboratory self-administration sessions, demonstrating a true physiological satiety effect for alcohol.
• Treatment-Seeking Populations: Among patients actively seeking care, GLP-1RAs serve as powerful multipliers when combined with standard behavioral interventions. When added to standardized cognitive behavioral therapy (CBT), semaglutide achieved a moderate-to-large effect size (Cohen’s d = 0.57 for heavy drinking days), vastly outperforming historic data for approved AUD medications.

The Dual Smoker/Drinker Phenotype

Finally, GLP-1RAs hold unique promise for patients with concurrent nicotine dependence. In a clinical trial of non-treatment-seeking AUD patients, semaglutide treatment predicted a significant, progressive reduction in cigarettes smoked per day over time among those who used tobacco. Because alcohol and nicotine use frequently co-occur and amplify one another’s reinforcing properties, finding a single agent capable of targeting the common reward pathways of both substances represents a Holy Grail in addiction therapeutics.

What Changes

Shifting Paradigms in Practice

The integration of GLP-1RAs into the treatment of AUD promises to alter the concrete logistics of care delivery, tracking, and clinical monitoring.

Shifting from Abstinence to Harm Reduction

For decades, traditional addiction treatment operated on a strict binary: complete abstinence or clinical failure. Modern addiction medicine has progressively shifted toward a harm-reduction model, recognizing that any net reduction in alcohol quantity or heavy drinking episodes yields substantial drops in healthcare costs, improvements in psychiatric functioning, and reductions in all-cause mortality.

The FDA and global health authorities now accept reductions in World Health Organization (WHO) risk drinking levels and heavy drinking days as valid primary endpoints for clinical success. Clinical trial data demonstrate that GLP-1RAs are uniquely tailored to this harm-reduction paradigm. Semaglutide primarily reduces the quantity of alcohol consumed per episode (drinks per drinking day) and prevents a standard drinking day from escalating into a heavy drinking day, rather than merely changing the frequency of drinking days. It provides a pharmacological “brake,” allowing patients to regain control over compulsive consumption.

Unprecedented Clinical Efficacy Metrics

To contextualize how clinical practice will change, providers must compare the number needed to treat (NNT) for GLP-1RAs against historic standards. In the 2026 semaglutide trial, the NNT for a clinically meaningful, 2-level decrease in the WHO risk drinking level was 4.3. Traditional FDA-approved medications such as acamprosate and naltrexone typically have an NNT of 7 or higher for comparable endpoints. Implementing therapies with this magnitude of effect could drastically enhance the success rates of outpatient addiction programs.

Practical Practice Modifications for Providers

When integrating incretin mimetics into substance use care, several clinical protocols must be adapted:

1. Intensive Blinding and Expectations Management: In clinical trials, the prominent side effects of GLP-1RAs (e.g., weight loss and gastrointestinal effects) pose a substantial risk of “functional unblinding,” in which patients and unmasked providers infer they are on the active drug. In routine clinical practice, providers must manage patient expectations, ensuring they understand that while the medication dramatically reduces biological craving, it works best as an adjunct to behavioral therapy.
2. Gastrointestinal Vulnerability Profiling: Patients with AUD have a baseline gastrointestinal vulnerability due to chronic alcohol-induced mucosal changes. Data show that GI adverse events (nausea, constipation, vomiting, and reflux) occur slightly more frequently in AUD populations taking semaglutide than in standard obesity cohorts. Providers must use slower, highly individualized dose-titration schedules and consider proactive antiemetic management to prevent premature treatment discontinuation.
3. Rigorous Pancreatic and Lab Safety Monitoring: Given the historical association between heavy alcohol use and acute pancreatitis, as well as the known pancreatic profile of GLP-1RAs, monitoring pancreatic enzymes is vital. Fortunately, in closely monitored clinical trials of semaglutide and exenatide for AUD, no cases of acute pancreatitis were reported, though transient, asymptomatic elevations in plasma amylase do occur.
4. Addressing Administrative and Logistical Compliance: Outpatient addiction treatment typically suffers from high attrition rates. Incorporating structured, weekly or biweekly medical touchpoints—such as pairing a weekly subcutaneous injection with a regular behavioral therapy session—can significantly improve trial retention and ensure long-term medication adherence.

Are We There Yet?

Are we ready to universally prescribe GLP-1RAs for alcohol use disorder? Not quite, but the destination is firmly in sight. Broad off-label use across all patient populations cannot yet be universally endorsed due to ongoing safety uncertainties in lean cohorts and a lack of long-term follow-up data after discontinuation.

However, for patients who simultaneously struggle with the dual burdens of obesity and moderate-to-severe alcohol use disorder, the evidence supporting semaglutide is profoundly compelling. By bridging the treatment gap through primary care settings where GLP-1RAs are already widely prescribed, these agents have the potential to destigmatize addiction treatment and meet patients exactly where they are. Incretin therapy has expanded far beyond diabetes and weight management—it is poised to fundamentally redefine the future of recovery.

References

1. Klausen MK, Jensen ME, Møller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7(19):e159863. doi:10.1172/jci.insight.159863
2. Klausen MK, Justesen SK, Pedersen JN, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet. 2026;407(10537):1687-1698. doi:10.1016/S0140-6736(26)00123-X
3. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82(4):395-405. doi:10.1001/jamapsychiatry.2024.4789